Advancing Precision Oncology: Radionuclide Conjugate and Antibody-Drug Conjugate (ADC) Development Strategies

Alex MacDonald, PhD, Vice President, Model-Informed Drug Development, Allucent

Alex MacDonald is VP of Model-informed Drug Development at Allucent. He is an Engineer and Quantitative Pharmacologist by training, studying for a PhD in physiologically based pharmacokinetics and pharmacodynamics at the University of Sheffield, UK.

He has over 20 years of cross-pharma experience in modelling, clinical pharmacology and pharmacometrics and joined Allucent from AstraZeneca, where he was most recently Global Head of Respiratory and Immunology Clinical Pharmacology and Pharmacometrics. Alex is well-published across multiple therapeutic areas with different modalities including respiratory and immunology medicine, oncology and metabolic diseases.

Sugato De, MS, Vice President, Regulatory Strategy, Head of Medical Technology, Allucent

As a previous Senior Policy Advisor at the FDA, as well as a seasoned leader within the CRO industry, Sugato De has cultivated expertise in a plethora of regulatory pathways, including dossiers for combination products, expedited pathways, protocol development for medical devices and more. During his 11-year tenure with the Center for Devices and Radiological Health (CDRH) at the US FDA, Sugato developed specialized expertise in drug-device combination products, digital health technologies and critical care medicine.

Angela Brady, MHL, Senior Vice President, Global Head of Project Leadership and Client Relations, Allucent

With over 25 years of experience in global R&D clinical development and operations leadership, Angela Brady brings substantial depth and breadth of biotechnology and biopharmaceutical experience to the role of Senior Vice President and Global Head of Project Leadership and Client Relations at Allucent.

Angela has wide-ranging CRO experience, holding leadership roles in project and alliance management at many of the most acclaimed global CROs, including iQVIA, ICON and PPD, a Thermo Fisher company. Angela holds a Master’s Degree in Law from Shepard Broad College of Law, Nova Southeastern University, in Ft. Lauderdale, FL, and a Bachelor’s Degree in Chemistry from Tennessee Technological University in Cookeville, TN.

Dr. Brian Barnett, MD, Executive Medical Director, Oncology, Allucent

Prior to joining the industry, Dr. Brian Barnett, MD was a medical oncologist working in private practice. At Tulane University, he served as an Assistant Professor of Hematology and Medical Oncology, focusing on Regulatory T Cells in academic medicine. Along with Dr. Barnett’s experience in clinical practice, he has accumulated over 20 years of industry experience in translational research, medical monitoring, and regulatory meeting preparations. Dr. Barnett has held various impactful roles throughout his time in the pharmaceutical space, including Chief Medical Officer. At Allucent, Dr. Barnett provides the A-Team with expert guidance on both early- and late-stage drug and cell therapy clinical development.